Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5498056 | International Journal of Radiation Oncology*Biology*Physics | 2017 | 20 Pages |
Abstract
These results suggest that certain patients with intermediate- or high-risk prostate cancer treated with brachytherapy might not benefit from the addition of EBRT. A randomized controlled trial of brachytherapy plus ADT with or without EBRT for unfavorable intermediate- and favorable high-risk organ-confined prostate cancer should be undertaken.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
David D. BA, Vinayak MD, MSc, Paul L. MD, Ivan PhD, Neil E. MD, MPH, Kent W. MD, PhD, Phillip M. MD, Quoc-Dien MD, Peter F. DO, MS, Martin T. MD, PhD,